Novo Nordisk A/S
NONOF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $100,988,000 | $83,683,000 | $55,525,000 | $47,757,000 |
| Dep. & Amort. | $8,545,000 | $9,413,000 | $7,362,000 | $6,025,000 |
| Deferred Tax | $26,203,000 | $20,991,000 | $13,537,000 | $11,323,000 |
| Stock-Based Comp. | $2,289,000 | $2,149,000 | $1,539,000 | $1,040,000 |
| Change in WC | -$11,995,000 | -$12,245,000 | -$5,336,000 | -$8,656,000 |
| Other Non-Cash | -$5,062,000 | $4,917,000 | $6,459,000 | -$2,489,000 |
| Operating Cash Flow | $120,968,000 | $108,908,000 | $78,887,000 | $55,000,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$47,164,000 | -$25,806,000 | -$12,146,000 | -$7,385,000 |
| Net Acquisitions | -$82,163,000 | $0 | -$7,075,000 | -$18,283,000 |
| Inv. Purchases | -$19,814,000 | -$13,289,000 | -$9,735,000 | -$7,113,000 |
| Inv. Sales/Matur. | $24,391,000 | $8,293,000 | $6,645,000 | $1,172,000 |
| Other Inv. Act. | -$4,145,000 | -$13,090,000 | -$2,607,000 | -$1,046,000 |
| Investing Cash Flow | -$128,895,000 | -$43,892,000 | -$24,918,000 | -$31,605,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $73,056,000 | -$1,467,000 | -$2,408,000 | $15,471,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$20,181,000 | -$29,924,000 | -$24,086,000 | -$19,447,000 |
| Dividends Paid | -$44,140,000 | -$31,767,000 | -$25,303,000 | -$21,517,000 |
| Other Fin. Act. | $0 | $0 | $0 | $0 |
| Financing Cash Flow | $8,735,000 | -$63,158,000 | -$51,797,000 | -$25,493,000 |
| Forex Effect | $455,000 | -$119,000 | -$238,000 | $591,000 |
| Net Chg. in Cash | $1,263,000 | $1,739,000 | $1,934,000 | -$1,507,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $14,392,000 | $12,653,000 | $10,719,000 | $12,226,000 |
| End Cash | $15,655,000 | $14,392,000 | $12,653,000 | $10,719,000 |
| Free Cash Flow | $69,659,000 | $70,012,000 | $64,134,000 | $47,615,000 |